$50.5 B

BSX Mkt cap, 04-Dec-2018

$2.4 B

Boston Scientific Revenue Q3, 2018
Boston Scientific Gross profit (Q3, 2018)1.7 B
Boston Scientific Gross profit margin (Q3, 2018), %71.9%
Boston Scientific Net income (Q3, 2018)432 M
Boston Scientific EBIT (Q3, 2018)388 M
Boston Scientific Cash, 30-Sep-2018168 M
Boston Scientific EV55.2 B

Boston Scientific Revenue

Boston Scientific revenue was $9.05 b in FY, 2017

Embed Graph

Boston Scientific Revenue Breakdown

Embed Graph

Boston Scientific revenue breakdown by business segment: 35.3% from MedSurg, 24.8% from Rhythm Management and 39.9% from Cardiovascular

Boston Scientific Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

7.1b7.4b7.5b8.4b9.0b

Revenue growth, %

3%1%12%

Cost of goods sold

2.2b2.2b2.2b2.4b2.6b

Gross profit

5.0b5.2b5.3b6.0b6.5b

Gross profit Margin, %

70%70%71%71%71%

R&D expense

997.0m

General and administrative expense

3.3b

Operating expense total

4.3b

Depreciation and amortization

565.0m

EBIT

120.0m(301.0m)(327.0m)447.0m1.3b

EBIT margin, %

2%(4%)(4%)5%14%

Interest expense

324.0m216.0m284.0m233.0m229.0m

Pre tax profit

(223.0m)(509.0m)(650.0m)177.0m933.0m

Income tax expense

(102.0m)(390.0m)(411.0m)(170.0m)828.0m

Net Income

(121.0m)(119.0m)(239.0m)347.0m104.0m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.7b1.8b1.9b1.8b1.8b1.8b1.9b2.0b2.1b2.1b2.2b2.3b2.2b2.4b2.5b2.4b

Cost of goods sold

510.0m537.0m563.0m550.0m520.0m540.0m539.0m573.0m639.0m594.0m650.0m632.0m637.0m672.0m739.0m672.0m

Gross profit

1.2b1.2b1.3b1.3b1.2b1.3b1.3b1.4b1.5b1.5b1.5b1.6b1.6b1.7b1.8b1.7b

Gross profit Margin, %

71%70%70%70%71%71%71%71%70%72%70%72%71%72%70%72%

R&D expense

217.0m191.0m206.0m212.0m192.0m220.0m221.0m210.0m222.0m232.0m235.0m244.0m254.0m261.0m275.0m289.0m

General and administrative expense

658.0m666.0m743.0m741.0m668.0m700.0m729.0m716.0m779.0m772.0m794.0m815.0m800.0m860.0m886.0m870.0m

Operating expense total

875.0m857.0m949.0m953.0m860.0m920.0m950.0m926.0m1.0b1.0b1.0b1.1b1.1b1.1b2.3b1.2b

Depreciation and amortization

101.0m109.0m109.0m109.0m116.0m131.0m136.0m135.0m136.0m143.0m142.0m139.0m141.0m147.0m148.0m

EBIT

103.0m197.0m(69.0m)64.0m24.0m219.0m(299.0m)293.0m(334.0m)348.0m364.0m225.0m377.0m407.0m392.0m388.0m

EBIT margin, %

6%11%(4%)3%1%12%(16%)15%(16%)17%17%10%17%17%16%16%

Interest expense

137.0m54.0m53.0m54.0m60.0m106.0m58.0m59.0m59.0m58.0m57.0m58.0m57.0m61.0m57.0m58.0m

Pre tax profit

(40.0m)146.0m(104.0m)3.0m(51.0m)105.0m(367.0m)228.0m(397.0m)257.0m305.0m91.0m309.0m323.0m347.0m456.0m

Income tax expense

(35.0m)13.0m(108.0m)(40.0m)(50.0m)3.0m(169.0m)26.0m(190.0m)29.0m15.0m(55.0m)26.0m26.0m(209.0m)24.0m

Net Income

(5.0m)133.0m4.0m43.0m(1.0m)102.0m(198.0m)202.0m(207.0m)228.0m290.0m146.0m283.0m298.0m555.0m432.0m

Boston Scientific Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

217.0m587.0m319.0m196.0m188.0m

Accounts Receivable

1.5b

Inventories

897.0m946.0m1.0b955.0m1.1b

Current Assets

3.0b3.6b3.5b3.2b3.8b

PP&E

1.5b1.5b1.5b1.6b1.7b

Goodwill

5.7b5.9b6.5b6.7b7.0b

Total Assets

16.6b17.0b18.1b18.1b19.0b

Accounts Payable

246.0m262.0m209.0m447.0m530.0m

Short-term debt

Current Liabilities

1.8b2.8b2.4b3.6b5.7b

Long-term debt

4.2b3.9b5.7b5.4b3.8b

Total Debt

4.2b3.9b5.7b5.4b3.8b

Additional Paid-in Capital

16.6b16.7b16.9b17.0b17.2b

Retained Earnings

(8.6b)(8.7b)(8.9b)(8.6b)(8.4b)

Total Equity

6.5b6.5b6.3b6.7b7.0b

Debt to Equity Ratio

0.6 x0.6 x0.9 x0.8 x

Debt to Assets Ratio

0.3 x0.2 x0.3 x0.3 x

Financial Leverage

2.5 x2.6 x2.9 x2.7 x2.7 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

571.0m191.0m357.0m246.0m242.0m903.0m350.0m338.0m438.0m237.0m156.0m195.0m210.0m287.0m208.0m168.0m

Accounts Receivable

1.2b1.2b1.3b1.2b1.2b1.2b1.3b1.3b1.4b1.4b1.4b1.4b1.5b1.6b1.6b1.6b

Inventories

895.0m926.0m949.0m989.0m958.0m968.0m1.1b1.0b981.0m998.0m971.0m1.0b1.1b1.1b1.1b1.1b

Current Assets

3.5b2.9b3.2b3.2b3.2b3.8b3.5b3.2b3.3b3.2b3.0b3.2b3.5b4.1b3.9b4.0b

PP&E

1.5b1.5b1.5b1.5b1.5b1.5b1.5b1.5b1.5b1.5b1.7b1.7b1.7b1.7b1.7b1.7b

Goodwill

5.6b5.7b5.7b5.9b5.9b5.9b6.5b6.5b6.5b6.5b6.7b6.9b6.9b7.0b7.2b7.6b

Total Assets

16.9b16.3b16.5b16.7b16.5b17.1b18.2b17.7b17.8b17.7b17.9b18.4b18.6b19.2b19.6b20.4b

Accounts Payable

238.0m241.0m241.0m234.0m228.0m191.0m210.0m232.0m284.0m298.0m376.0m376.0m371.0m404.0m403.0m453.0m

Current Liabilities

1.9b1.7b1.8b1.8b2.5b1.9b2.2b2.6b3.2b3.0b3.5b4.3b4.8b5.0b4.8b5.1b

Long-term debt

4.2b4.2b4.3b4.2b3.8b5.1b5.8b5.4b5.2b5.2b5.5b4.8b4.4b4.8b4.8b4.8b

Total Debt

4.2b4.2b4.3b4.2b3.8b5.1b5.8b5.4b5.2b5.2b5.5b4.8b4.4b4.8b4.8b4.8b

Additional Paid-in Capital

16.5b16.6b16.6b16.7b16.8b16.8b16.8b16.8b16.9b17.0b17.0b17.1b17.1b17.2b17.2b17.3b

Retained Earnings

(8.7b)(8.4b)(8.4b)(8.4b)(8.7b)(8.6b)(8.8b)(8.7b)(8.9b)(8.7b)(8.2b)(8.1b)(7.8b)(8.3b)(7.8b)(7.3b)

Total Equity

6.6b6.4b6.5b6.2b6.5b7.1b7.2b7.6b7.0b7.7b8.3b

Debt to Equity Ratio

0.8 x0.9 x0.8 x0.8 x0.8 x0.8 x0.7 x0.7 x0.6 x0.6 x

Debt to Assets Ratio

0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.2 x0.2 x

Financial Leverage

2.6 x2.8 x2.7 x2.9 x2.7 x2.5 x2.5 x2.5 x2.7 x2.5 x2.5 x

Boston Scientific Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(121.0m)(119.0m)(239.0m)347.0m104.0m

Depreciation and Amortization

844.0m

Accounts Receivable

(101.0m)53.0m(17.0m)(216.0m)(30.0m)

Inventories

(7.0m)(81.0m)3.0m40.0m(107.0m)

Accounts Payable

(37.0m)620.0m(20.0m)553.0m195.0m

Cash From Operating Activities

1.1b1.3b600.0m972.0m1.4b

Purchases of PP&E

(245.0m)(259.0m)(247.0m)(376.0m)(319.0m)

Cash From Investing Activities

(1.0b)

Interest Paid

329.0m221.0m283.0m233.0m235.0m

Income Taxes Paid

67.0m74.0m80.0m94.0m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Net Income

(5.0m)133.0m4.0m43.0m(1.0m)

Cash From Operating Activities

809.0m198.0m483.0m829.0m

Purchases of PP&E

(161.0m)(59.0m)(124.0m)(180.0m)

Cash From Investing Activities

(112.0m)(65.0m)(189.0m)(662.0m)

Boston Scientific Ratios

USDY, 2018

EV/EBIT

142.2 x

Debt/Equity

0.6 x

Debt/Assets

0.2 x

Financial Leverage

2.5 x
Report incorrect company information

Boston Scientific Operating Metrics

Boston Scientific's Customers was reported to be 35 k in FY, 2016.
FY, 2016

Countries

120

Customers

35 k

Facilities

13
Report incorrect company information

Boston Scientific Employee Rating

4.01402 votes
Culture & Values
4.1
Work/Life Balance
3.8
Senior Management
3.7
Salary & Benefits
3.9
Career Opportunities
3.7
Source